Chronic kidney disease kills more older cats than almost any other condition. By some veterinary estimates, up to half of cats over age 15 show signs of it, and once the kidneys begin to fail, current treatments can only slow the decline. Now a University of Tokyo spinoff is reportedly pushing to change that, seeking regulatory approval in Japan for a drug built around a protein that could address the root cause of the disease rather than just its symptoms.
The therapy is based on a recombinant version of apoptosis inhibitor of macrophage, or AIM, a protein that helps kidneys flush out dead cells and debris. The startup, which emerged from the laboratory of immunologist Toru Miyazaki, has not been publicly named in regulatory filings, and Japan’s Ministry of Agriculture, Forestry and Fisheries has not confirmed receipt of a formal application as of May 2026. The claim that the company “seeks approval” originates from press reporting and university communications rather than from any confirmed regulatory filing or official company statement. The scientific groundwork is substantial, and the clinical data published so far has drawn attention from veterinarians and cat owners worldwide, but the regulatory status of the project remains unverified by independent sources.
Why cats are uniquely vulnerable
A peer-reviewed paper published in Scientific Reports, part of the Nature Portfolio, laid out the genetic and molecular explanation. Miyazaki’s team showed that cats produce AIM protein in a form that fails to activate in their bloodstream. In most mammals, AIM detaches from a carrier molecule and travels to the kidneys, where it helps clear necrotic material from renal tubules. In cats, the protein stays locked to its carrier, leaving cellular waste to pile up and drive progressive kidney damage.
That finding solved a long-standing veterinary puzzle. Cats develop chronic kidney disease at far higher rates than dogs, humans, or most other species, and until Miyazaki’s work, no one had a clear biological explanation. The discovery also pointed toward a potential fix: if you could supply cats with a functional version of AIM, you might be able to restore the kidney’s natural waste-clearance system.
From lab bench to sick cats
An exploratory clinical evaluation, indexed on ScienceDirect, tested recombinant AIM (rAIM) in cats with advanced chronic kidney disease. The study measured markers of uremia, tracked survival, and monitored for safety signals. It also documented how the protein was manufactured and administered, laying groundwork for a future regulatory submission.
The results were encouraging but preliminary. The trial was small and exploratory, not a large-scale pivotal study with the statistical power regulators typically demand for full marketing authorization. No subsequent trial results or follow-up cohorts have appeared in the peer-reviewed record. Whether the startup has completed additional blinded, controlled studies behind closed doors, or whether Japanese regulators might accept the existing data under a conditional or accelerated pathway, remains unknown.
Open questions on safety and timeline
One concern flagged in both the published research and a University of Tokyo profile on Miyazaki’s work is immunogenicity. Because rAIM is a recombinant protein, a cat’s immune system could produce antibodies against it after repeated doses, potentially neutralizing the drug or triggering adverse reactions. Long-term safety monitoring, including serial bloodwork and extended post-treatment observation, would normally be required before regulators sign off. No comprehensive safety registry or large pharmacovigilance dataset for rAIM has been made public.
The regulatory timeline is equally opaque. Veterinary drug reviews in Japan can stretch from months to years depending on the completeness of the evidence package. Without confirmed filings from the Ministry of Agriculture, Forestry and Fisheries, independent observers cannot determine whether the project is in late-stage review, early dialogue with authorities, or still assembling its dossier.
How rAIM differs from the only approved feline kidney drug
Pet owners tracking headlines about new kidney treatments should note an important distinction. In the United States, the FDA has conditionally approved Varenzin-CA1, a molidustat oral suspension, for nonregenerative anemia associated with feline chronic kidney disease. It was the first drug cleared in the U.S. specifically for that complication.
But Varenzin-CA1 targets a downstream problem: the drop in red blood cell production that accompanies kidney failure, not the kidney deterioration itself. The rAIM approach attempts something more ambitious: restoring the organ’s ability to clear cellular waste before damage becomes irreversible. The two therapies are not direct competitors. In theory, they could complement each other if both were approved in the same market and found to be compatible, though no head-to-head or combination data exists.
The FDA’s conditional approval pathway also offers a useful benchmark. Even under that expedited framework, regulators required controlled studies, manufacturing quality data, and a commitment to ongoing evidence generation. Post-marketing adverse events are tracked through the federal safety reporting portal. For the Japanese rAIM effort, no equivalent regulatory correspondence, safety summaries, or public review documents are available, leaving a much thinner evidence trail for outside evaluation.
What this means for cat owners right now
The science behind rAIM is real and well-grounded. A plausible biological mechanism, backed by peer-reviewed research and early clinical data, sets it apart from the many unproven supplements marketed to owners of cats with kidney disease. But “promising” is not the same as “proven,” and no cat owner should delay or alter current treatment based on a drug that has not yet cleared regulatory review.
The standard of care for feline chronic kidney disease still rests on specialized renal diets, fluid management, blood pressure control, phosphorus binders, and treatment of secondary complications like anemia with approved therapies where available. Owners whose cats might be candidates for an experimental program should talk with their veterinarians, confirm that any study has formal ethics oversight, and ask for written information on potential benefits and risks.
If rAIM ultimately wins approval, it would represent a genuine shift in how veterinary medicine treats one of the most common killers of aging cats. For now, it remains a scientifically grounded hope waiting on the data and regulatory scrutiny that will determine whether it delivers on its promise.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
